Drug Developers Look to Deuterated Drugs as Risk Managed Opportunity
Recently, the number of articles about deuterated drugs has moved to a new level following FDA approval of Teva’s Austedo for the treatment of chorea associated with Huntington’s disease. One of the often-cited advantages of replacing hydrogen with deuterium is the effect that heavy hydrogen atoms can have on drug half-life. To the extent that the drug remains in the system longer there is the possibility that dosing frequency can be reduced.
Currently, there are about a dozen companies actively pursuing the deuterated drug market. The majority are smaller drug formulators and developers, often relying on partnerships for co-development and/or marketing and distribution. Patents are expected to play a major role in this segment, largely because the majority of deuterated drugs under development are approved APIs in undeuterated form. This dynamic has given rise to a significant level of defensive IP activity, in which companies patent deuterated APIs largely on speculation that the drug will prove to be efficacious and safe at some point in the future.
The potential for defensive acquisition and investment is also factoring into the response of existing API rights holders. In this scenario, a non-deuterated API patent holder may invest in a company in the deuterated drug space that is developing a deuterated version of the API, giving the investing company the ability to leverage the timing of an eventual FDA filing to minimize the negative competitive impact of a deuterated product version on existing product revenue.
There are currently about two dozen potentially important deuterated drugs in development. Many of these drugs are pursuing therapeutic targets in important markets that include neurotransmitter regulation, transmembrane conductance, protease inhibition, inflammation, mitochondrial function modulation and antineoplasticity.
The findings of a recent survey of the deuterated drug market are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Deuterated Drugs: Products, Pipelines, Strategies, Therapeutics and Markets has been created to provide readers with information and data to assist them in understanding and effectively evaluating the market and competitive landscape for deuterated drugs. The report includes technology assessments, therapeutic target analysis, patent and product positioning strategies, therapeutic factors, near-term markets and market participant profiles.
More information is available at http://www.greystoneassociates.org
Source: Greystone Research Associates
Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Drug Developers Look to Deuterated Drugs as Risk Managed Opportunity here
News-ID: 653061 • Views: 238
More Releases from Greystone Research Associates
Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from
More Releases for API
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The
Global Biotech API Market Analysis
RNCOS has recently added a new Market Research Report titled, “Global Biotech API Market Analysis” to its report gallery. Biotech APIs contribute a very low share in the global API market with synthetic API’s accounting for majority of the formulations. However, with the revolutionary growth in the biopharmaceutical industry and gaining applications of biotech drugs, biotech API’s are sure to see a highly prospective market in the future. As per our